The malignant B cells of non -Hodgkin's lymphoma ( B -NHL cells ) express peptides derived from tumor -specific antigens such as immunoglobulin idiotypes, and also express major histocompatibility complex antigens. However, they do not express costimulatory molecules, which likely contributes to their protection from host antitumor immunity. To stimulate NHL -specific immune responses, we attempted to transfer the human CD40 ligand ( hCD40L ) gene to B -NHL cells and enhance their costimulatory potential. We found that an adenoviral vector encoding human CD40L ( AdhCD40L ) was ineffective at transducing B -NHL cells because these cells lack the coxsackievirus B -adenovirus receptor and v integrins. However, preculture of the B -NHL cells with the human embryonic lung fibroblast line, MRC -5, significantly up -regulated expression of integrin v 3 and markedly increased their susceptibility to adenoviral vector transduction. After prestimulation, transduction with AdhCD40L increased CD40L expression on B -NHL cells from 1.3 0.2% to 40.8 11.9%. Transduction of control adenoviral vector had no effect. Expression of transgenic human CD40L on these CD40 -positive cells was in turn associated with up -regulation of other co -stimulatory molecules including B7 -1 / -2. Transduced B -NHL cells were now able to stimulate DNA synthesis of autologous T cells. However, the stimulated T cells were unable to recognize unmodified lymphoma cells, a requirement for an effective tumor vaccine. Based on previous results in an animal model, we determined the effects of combined use of B -NHL cells transduced with AdhCD40L and AdhIL2 vectors. The combination enhanced initial T -cell activation and generated autologous T cells capable of specifically recognizing and killing parental ( unmodified ) B -NHL cells via major histocompatibility complex ± restricted cytotoxic T lymphocytes. These findings suggest that the combination of CD40L and IL2 gene -modified B -NHL cells will induce a cytotoxic immune response in vivo directed against unmodified tumor cells.
N on -Hodgkin's lymphoma ( NHL ) has heterogeneous molecular and immunophenotypic features, but over 80% express a B-cell phenotype.
1,2 Low -grade NHL can be cured with conventional radio -and/ or chemotherapy only if it is localized, 3 ± 5 and the benefits of high -dose regimens for more extensive disease are yet to be determined. For patients with high -grade lymphoma, current therapy is curative in less than 50%. 6 The use of high -dose chemotherapy for patients in remission may increase survival in the highestrisk subset, 7 but late complications of myeloablative therapy, including myelodysplasia and secondary leukemia, are being increasingly recognized. 8, 9 Because of the limitation of current therapies, other strategies including immunotherapy have been increasingly investigated.
Passive immunotherapy of lymphoma with humanized monoclonal anti -CD20 10, 11 or with radioimmunoconjugates 12 has also had remarkable activity against NHL. Active immunotherapy has focused on the recruitment of T-cell ± dependent and ± independent cytotoxic effector mechanisms using the infusion of immunostimulatory cytokines such as interleukin -2 (IL2 ) 13 ± 15 or interferon-( IFN -). 16 Improved outcomes have been reported when these approaches are used with chemotherapy or as maintenance after initial cytoreductive treatment. There has also been interest in developing specific T-cell immunity directed against lymphoma cells. Lymphoid lineage -specific antigens and hypervariable and idiotype immunoglobulin sequences have been identified as potential targets.
tion. 21 It is also expressed on the majority of follicular lymphoma cells, and when it is stimulated by CD40L, there is an up -regulation of costimulatory/ adherent molecules at the surface of malignant B cells, enhancing their capacity to elicit an immune response. 22, 23 In an animal model, we showed that combined expression of transgenic CD40L and transgenic IL2 could greatly enhance the antilymphoma immune response, compared to either transgene alone. 24 We have now determined whether such effects can be produced against fresh NHL -B cells from patients with low -grade follicular lymphoma or highgrade diffuse large cell lymphoma, using adenoviral vectors to transfer the CD40L and IL2 transgenes, and patient ( autologous ) T cells as the immune effectors.
MATERIALS AND METHODS

Cells
All human materials were obtained on Institutional Review Board± approved protocols. Single -cell suspensions of lymphoma cells were made by homogenization of lymph nodes with histologically and immunophenotypically confirmed infiltration of B -NHL cells. The diagnosis of B -NHL was based on the Revised European ± American Lymphoma Classification 1 and the tumors were immunophenotyped by flow cytometry. Tumor cells were enriched by incubation of the suspension with CD19 + magnetic beads (Miltenyi Biotech, Auburn, CA ) for 15 minutes at 6 ± 128C. After washing, the cells were applied to an MS + Separation Figure 1 . Lymphoma cells from a representative NHL patient before ( middle column ) or after coculture with MRC -5 were stained with PEconjugated anti -CD20 and CAR ( second row ) or V integrins ( third and fourth rows ). GFP expression was assessed 72 hours after AdGFP transduction ( 5Â10 3 vp / cell, bottom row ). Percentages of Ad receptors or GFP -positive cells in the CD20 + population are shown in histograms. Mean fluorescence intensity is shown in italics. Control cells RPMI8226 were used to demonstrate inducibility of CAR expression by the technique adopted.
Cancer Gene Therapy, Vol 8, No 5, 2001 TAKAHASHI, YOTNDA, ROUSSEAU, ET AL: CD40L/IL2-MEDIATED AUTOLOGOUS IMMUNE RESPONSE Column with a MiniMACS magnet ( Miltenyi Biotech ). These B cells were defined as monoclonal by / expression ratios. For isolation of autologous T cells, the CD19 -negative fraction was incubated with CD3 + magnetic beads and selected using an equivalent MiniMACS. The T cells collected were > 90% CD3 -positive by flow cytometry. Cells were frozen in DMSO freeze medium ( Igen International, Gaithersburg, MD ) and stored in liquid nitrogen.
MRC -5 cells, a human embryonic lung fibroblast cell line, were obtained from the American Type Culture Collection ( ATCC; Rockville, MD ) and cultured in RPMI 1640 medium supplemented with 10% heat -inactivated fetal bovine serum (Summit Biotechnology, Fort Collins, CO ).
Adenoviral vector and transduction of B -NHL cells
The construction of Ad vectors encoding green fluorescent protein (AdGFP), human IL2 ( AdhIL2 ), human CD40L ( AdhCD40L ), and initial transduction of B -NHL cells was described previously. 25 Cryopreserved B -NHL cells were thawed, washed, and stimulated. After stimulation, as described in Results, 1Â10 6 B -NHL cells were resuspended in 0.5 mL of culture medium with Ad vector at 378C in 5% CO 2 . After 2 hours, 1.5 mL of culture medium was added and the cells were maintained at 378C until analyzed.
Monoclonal antibodies ( MAbs ) and flow cytometry
Integrin -V 5 ± and mouse -IgG1± specific MAbs; fluorescein isothiocyanate -labeled MAbs specific for human CD20, IFN -, and goat antimouse immunoglobulin G ( GAM ); phycoerythrin (PE )-labeled MAbs specific for human CD13, CD20, CD154 (CD40L ), CD80, and IL4; and peridinin chlorophyll protein (PerCP) -labeled CD3 were all purchased from Becton Dickinson (San Jose, CA ). Human CD86 -specific PE -labeled and human integrin -V 3 ( CD51 / CD61 )± specific fluorescein isothiocyanate ±labeled MAbs were obtained from PharMingen ( San Diego, CA ). Coxsackievirus B -adenovirus receptor-specific MAb ( RmcB ) 26, 27 was prepared in our center from ATCC no. CRL -2379.
Staining procedures for surface phenotype and intracellular cytokine analysis were performed according to manufacturer's recommendation. All analyses were performed on a FACSCalibur flow cytometer (Becton Dickinson ) equipped with 488 -nm argon and 633-nm HeNe lasers. Gates were set using appropriate isotype control antibodies.
Enzyme -linked immunosorbent assay ( ELISA ) for cytokine measurement
Fresh culture medium was added to cells and 24 or 48 hours later, cell -free supernatant was harvested and stored at À 808C for IL2 ± and IFN -± specific ELISA (R&D Systems, Minneapolis, MN ), respectively. The amount of cytokine was normalized to the cell number at the time of supernatant harvest.
Generation of effector T cells
Autologous T cells were placed in X -vivo -10 medium supplemented with 2 mmol /L L -glutamine, 5% human heat -inactivated AB serum (BioWhittaker, NJ ) at 2Â10 5 cells/ mL, and stimulated with -irradiated ( 40 Gy ) unmodified B -NHL (U -NHL ) cells or with AdhCD40L-transduced B -NHL cells ( CD40L -NHL ) and Ad -hIL2± transduced B -NHL cells (IL2-NHL ), either alone or in combination ( CD40L +IL2 -NHL) at a T cell:stimulator ratio of 1 ± 2:1. Cultures were performed in a humidified 5% CO 2 incubator at 378C and restimulated weekly for 21 days. Cells were studied 7 days after the last stimulation.
Primary and secondary proliferation assay and IFNproduction assay Autologous T cells (1Â10 5 ) were cultured in X -vivo -10 culture medium with -irradiated (40 Gy ) unmodified B-NHL cells (0.5Â10 5 ) in V-bottomed 96 -well plates ( triplicate cultures ). Cell supernatants were harvested 48 hours after the initiation of culture for IFN -ELISA, as described above, and cultures were pulsed with 1 Ci of [ 3 H ]thymidine on day 3. Eighteen hours later, the cells were harvested onto glass fiber filters ( Brandel, Gaithersburg, MD ), and [ 3 H ]thymidine incorporation measured using a liquid scintillation analyzer ( Packard Instrument, Meriden, CT ). The stimulation index ( SI) was calculated as cpm ( T cells + NHL ) /cpm ( T cells ) .
Cytotoxic activity of autologous T -cell ± derived NHL -specific cytotoxic T lymphocyte ( CTL ) lines
The cytotoxicity of each CTL line was analyzed in a standard 4 -hour 51 Cr release assay. Target cells included autologous unmodified B -NHL cells and the K562 cell line, which is sensitive to killing by natural killer cells. After labeling with 51 Cr, the target cells were washed five times and plated at 5Â10 3 cells per well at an effector:target ratio of 50:1, 25:1, 10:1, and 5:1. After 4 hours, supernatants were harvested and 51 Cr release measured. To determine whether cytolysis was restricted by HLA class I, target cells were preincubated for 30 minutes with 10 g /mL of W6/ 32 ( Dako, Carpinteria, CA ), a MAb that recognizes a monomorphic HLA class I determinant. The presence of HLA class II ±restricted CTLs was measured using CR3 /43 (Dako ) at 10 g /mL, which recognizes HLA -DR, DP, DQ, and DX, as the blocking antibody. 
Statistical analysis
Student's t test was used to determine the statistical significance of differences between treatment groups. All data are presented as means one standard error of the mean ( SEM ).
RESULTS
Expression of Ad type 5 ( Ad5 ) receptors on B -NHL cells
High -efficiency infection of target cells by Ad5 requires binding to the primary receptor, Coxsackievirus B -adenovirus receptor, and to V integrins, 3 and 5. We examined the expression of these receptors on NHL cells using flow cytometry and appropriate MAbs ( Fig 1 ) . There was essentially no expression of any of these Ad receptors on B -NHL cells. However, expression of integrin V 3 was significantly up -regulated after co-culture with MRC -5 fibroblasts (P=.026, Table 1 ), a technique that we have previously shown to enhance Ad receptor expression on leukemic B cells. 25 Prestimulation did not alter expression of other Ad viral receptors.
Ad transduction of B -NHL cells
Malignant B cells were obtained from the lymph nodes of six B -NHL patients [ follicular lymphoma (FL ): n= 3; diffuse large cell lymphoma (DL ): n =3 ] and directly exposed to AdGFP. As anticipated from the low level of expression of Ad receptors on these cells (Table 1) , little transgene expression was obtained even at a multiplicity of infection (MOI) as high as 1.5Â10 4 viral particles ( vp )/cell ( Table  1 ) . When B-NHL cells were cultured for 24 hours with MRC -5 cells, the up-regulation of V 3 was associated with increased susceptibility to transduction and significant transgene expression was now detected in these cells using the same AdGFP vector (Fig 1 and Table 1 ). We next examined expression of a cell surface immunostimulatory transgene ( CD40L ) and a secreted cytokine (IL2) following transduction using the same Ad vector backbone and coculture system. Expression of the AdhCD40L transgene (Fig  2A and B ) and of AdhIL2 (Fig 3) Figure 2B ).
Autologous T -cell response induced by gene -modified B -NHL cells
We next determined whether transfer of the CD40L or IL2 genes, alone or in combination, would generate an anti -NHL ( Fig 4 ) . However, there was no increase in IFN -secretion by these stimulated T cells, implying absence of a Th1 response. Culture with IL-2± transduced NHL cells induced a statistically significant rise in both in [ 3 H ]thymidine incorporation (P < .003 compared to unmodified NHL cells) and IFN -secretion (P < .001 compared to unmodified NHL cells). The combination of both CD40L -and IL2 -gene ± transduced NHL cells also significantly increased thymidine incorporation ( P< .001 compared to unmodified NHL cells and P=.016 compared to IL2 alone in [ 3 H ]thymidine incorporation assay ). The superiority of the combination of CD40L -and IL2-transduced NHL cells over those expressing a single transgene was also evident in their ability to promote autologous T-cell growth. Autologous T cells were stimulated with irradiated parental -or gene -modified B -NHL cells weekly for 21 days, and harvested 7 days after the last stimulation. Stimulation by CD40L / NHL or IL2/NHL alone led to an overall reduction in the number of T cells (14% and 25% of starting numbers ), whereas the combination of CD40L + IL2 /NHL produced a 660% rise from starting numbers by week 4, as shown in Table 2 .
Table 2 also shows that there was no change in the CD4 / CD8 ratio after 4 weeks of culture, regardless of the stimulation used, but that the frequency of T cells expressing the activation antigen CD25 was increased after IL2 or CD40L + IL2 stimulation, but not by CD40L alone. IL4-positive (type 2 helper T) cells were unchanged by any stimulation, whereas the percentage of IFN -expressing CD3 + T cells was increased only by the CD40L and IL2 in combination, consistent with the increase of cytotoxic and/ or type 1 helper T (Th1 ) cells in the short -term cultures illustrated in Figure 4 .
To discover whether the increased T-cell growth and activation in the CD40L / IL2 NHL co -cultures translated to an increased specific effector function, we tested the ability of T cells from patients to proliferate in response to, and to kill autologous unmodified ( parental ) tumor cells. Figure 5 shows that only T cells derived from the combined CD40L and IL2 co -cultures were able to undergo secondary proliferation in response to stimulation with irradiated unmodified NHL cells. Similarly, only T cells stimulated by the combination of CD40L and IL2 had significant cytotoxic effector function against unmodified tumor cell targets ( Fig 6A and B ) . No cytotoxic activity was observed in T cells derived from cultures that contained NHL cells expressing CD40L or IL2 alone. The cytotoxicity induced by the CD40L /IL2 combination was due to MHC-restricted CTL because activity could be blocked by anti -HLA MAbs ( No Ab: 15.3 2.4%; anticlass I: 7.0 1.0%; P= .033; anticlass II: 8.7 2.6%; P=.133; n = 3). There was no discernible NK activity against K562 cells with any effector at any E:T ratio (data not shown ).
DISCUSSION
This study demonstrates that human primary NHL cells become susceptible to adenoviral vector ± mediated gene transfer after culture with fibroblasts, and can then be transduced to express immunomodulatory quantities of the hCD40L and hIL2 genes. Expression of these genes individually has little ability to generate an autologous antitumor T cell response ex vivo, but the combined expression of both CD40L and IL2 significantly enhances the proliferation and activation of co -cultured autologous T cells and also generates an MHC -restricted cytotoxic T-cell response. These ex vivo human responses are consistent with prior observations made in vivo in a murine model. Because the effect was observed when using either low -grade follicular lymphoma or high -grade large cell lymphoma cells, transfer of the combination of CD40L and IL2 genes by adenoviral vectors may be generally useful for generating immune response to human lymphoma cells.
The concept of using CD40L molecules as a component of immunotherapy for B -cell malignancies is based on several potential activities of the CD40 ±CD40L receptor ±ligand system. CD40 -activated malignant B cells have greatly increased ability to present their tumor-associated antigens due to up -regulation of co -stimulatory and cell adhesion molecules including the B7 family and LFA -1. 28 Such an effect has been seen using soluble CD40L, when follicular lymphoma B cells were shown to be able to generate allostimulation. 22 Our own studies show an identical effect on phenotype using transgenic CD40L, which presumably produces these effects by a combination of autocrine and paracrine stimulation of CD40. Expression of CD40L also enhances the maturation of professional antigen-presenting cells 29, 30 and co -stimulates antigen -activated and CD40 -expressing T cells. 31 ± 33 Both these effects may favor an antitumor immune response. Finally, CD40 stimulation, at least by soluble CD40L, may induce a direct growthinhibitory effect in lines derived from large cell NHL and Burkitt lymphoma cells. 34 ± 36 These immunomodulatory and growth inhibitory effects notwithstanding, CD40L alone has proved a relatively weak stimulator of antitumor immunity. Only when it is combined with agents such as recombinant IL2 and IFN -have significant antitumor effects been seen preclinically. 24 This requirement for dual stimulation evidently extends to transgenically expressed (cellular ) CD40 and IL2 on human primary low -grade and highgrade lymphoma cells.
How may the combination of CD40L and IL2 gene expression by NHL cells have synergistic effects on autologous T-cell proliferation and antitumor effector function? One possible sequence of events is that tumor antigen± specific T cells engage their TCR on the tumor target cells, express CD40, are co -stimulated by transgenic CD40L, and then divide and become effector cells in response to transgenic IL2. In the absence of transgenic CD40L, tumor antigen± activated T cells fail to become effector cells even if IL2 is available. Conversely, in the absence of transgenic IL2, co -stimulated T cells will fail to expand.
Although the effects of CD40L and IL2 expression were apparently beneficial in this study, there are a number of potential concerns about the approach. CD40 stimulation via CD40L has been reported to inhibit apoptosis of lymphoma cell lines and could play a role in drug resistance. 37 However, CD40 activation of CLL cells did not impair Fasindependent, CTL -mediated apoptosis in a more recent study. 38, 39 Another concern is that recombinant human CD40L trimer has been reported to induce activation and proliferation of primary mantle cell lymphoma cells. 39, 40 Despite these potential concerns, animal and human preclinical data strongly support the use of IL2 and CD40L in combination for the generation of an antilymphoma immune response. Our results show that it is possible to transduce and express adequate amounts of these molecules in primary lymphoma cells using adenoviral vectors, provided the NHL cells have been cultured with fibroblasts to up -regulate expression of the V 3 integrin, which serves as an adenovector co-receptor. 40, 41, 42 We are currently testing the approach in a phase I study in patients with CD40 -positive B -NHL.
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